Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States.
Racial differences among hepatocellular carcinoma survival have been reported, but the etiology behind these disparities remains unclear. Using multi-variable logistic regression analysis, our restrospective cohort study investigated the demographic disparities in survival among localized hepatocellular carcinoma in the United States. From 1998 to 2001, 2,776 cases of localized hepatocellular carcinoma were identified. Significant racial/ethnic disparities in overall survival and utilization of therapies were identified. Compared with non-Hispanic white males, black females were 56% less likely to survive 3 years (OR 0.44; 95% CI 0.21-0.93). Treatment-specific models also demonstrated disparities, e.g., compared with non-Hispanic whites, Asians receiving transplantation were 77% more likely to survive 3 years (OR, 1.77; 95% CI 1.28-2.44). There are significant racial/ethnic disparities in 3-year survival among patients with localized hepatocellular carcinoma. These differences are partially explained by demographic differences in utilization of therapy and in stage-specific survival for each therapy.
Wong
Robert J
RJ
School of Medicine, University of California, San Francisco, Oakland, CA 94605, USA. RobertWong123@gmail.com
Corley
Douglas A
DA
D000367:Age Factors; D006528:Carcinoma, Hepatocellular / Q000208:ethnology / Q000401:mortality* / Q000628:therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000208:ethnology / Q000401:mortality* / Q000628:therapy; D008297:Male; D054547:National Cancer Institute (U.S.); D044469:Racial Groups; D018426:SEER Program; D012737:Sex Factors; D016019:Survival Analysis; D013997:Time Factors; D014481:United States / Q000453:epidemiology